Diabetic MRSA foot infection - Role of linezolid therapy

British Journal of Diabetes and Vascular Disease

Volumn 4, Issue 1, 2004, Pages 44-46

  Turner, Joanna M ^b   Hakeem, Lukman M ^b   Lockman, K Ann ^b   Bhattacharyya, Diptendu N ^b   Campbell, Ian W ^a  

^a VICTORIA HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Antibiotics; Diabetes; Foot ulcers; Infection; Linezolid; MRSA

Indexed keywords

ANTIBIOTIC AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GABAPENTIN; INSULIN; LINEZOLID; METICILLIN; NEUTRAL INSULIN; TRIMETHOPRIM; VANCOMYCIN; WARFARIN;

AGED; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATION; BLOOD CULTURE; CASE REPORT; CELLULITIS; CEREBROVASCULAR ACCIDENT; CONVALESCENCE; DIABETES CONTROL; DIABETIC FOOT; FEMALE; FOOT PAIN; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; LEG AMPUTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT TRANSPORT; PERCEPTIVE THRESHOLD; PREVALENCE; SENSORY NEUROPATHY; STAPHYLOCOCCUS INFECTION;

EID: 1542300203     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514040040010801     Document Type: Article

References (19)

1. Dang CN, Prasad YDM, Boulton AJM, Jude EB. Methicillin-resistant staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003;20:159-61.
2. Duckworth G. Controlling methicillin-resistant staphylococcus aureus: time to return to more stringent methods of control in the United Kingdom (editorial). BMJ 2003;327:1177-8.
3. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003;361:1545-51.
4. Reacher MH, Shah A, Livermore DM et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2003;320:213-16.
5. Public Health Laboratory Service. Staphylococcus aureus bacteraemia: England and Wales January to December 2000. Common Dis Rep CDR Wkly (serial online) 2001 (cited 5 September 2003): 11 (7) Bacteraemia. www.hpa.org.uk/cdr/PDFFiles/2001/cdr0701.pdf (accessed 30 Sep 2003).
6. Report on methicillin-resistant staphylococcus aureus bacteraemia in Scotland, SCIEH 18, November 2003.
7. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmaer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteraemia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
8. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJM. Methicillin-resistant staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabetic Med 1999;16:767-71.
9. Chambers HF. The changing epidemiology of staphylococcus aureus. Emerg Infect Dis 2001;7:178-82.
10. Munro N, Rich N, McIntosh C, Foster AVM, Edmundo ME. Infection in the diabetic foot. Br J Diabetes Vasc Dis 2003;3:132-6.
11. Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistant in staphylococci: epidemiology, molecular mechanisms and clinical relevance. Infect Dis Clin North Am 1997;11:813-49.
12. Hiramatsu K, Hanaki H, Ino T, Yabatu K, Oguri T, Tenover FC. Methicillin-resistant staphylococcus clinical strain with related reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
13. Centers for disease control and prevention. Staphylococcus aureus resistant to vancomycin - United States 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7.
14. Drew RH, Perfect Jr, Srinath L et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinuprisrin/dalfopristin in patients intolerant of or failing prior to therapy. Jantimicrob Chemother 2000;46:775-84.
15. Zurenko GE, Yagi BH, Schaadt RD et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-45.
16. Stevens DL, Smith LG, Bruss JB et al. for the linezolid skin and soft tissue infection study group. Randomised comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44:3408-13.
17. Stevens DL, Herr D, Lampiris H et al. and the linezolid MRSA Study Group. Linezolid versus vancomycin for the treatment of methicillin-resistant staphylococcus aurues (MRSA) infections. Clin Infect Dis 2002;34: 1481-90.
18. Lipsky BA, Itani K, Norden C. Linezolid Diabetic Foot Infections Study Group. Clin Infect Dis 2004;38:17-24.
19. Nathwani D. Impact of methicillin-resistant staphylococcus aureus infections on key health economic outcomes: does reducing the lenght of hospital stay mattet? J Antimicrob Chemother 2003;51(suppl S2):ii 37-ii 44.